Top Markets
Coin of the day
Synairgen plc Synairgen plc

Synairgen plc

SNG
Classement en actions #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Prix de l'action
$0.01292666
Dernière synchronisation: 2025-04-08
Capitalisation boursière
$157.54K
Changement (1 jour)
6.84%
Changement (1 an)
0.00%
Pays
GB
Échange Synairgen plc (SNG)

Catégorie

Historique des dividendes pour Synairgen plc (SNG)
Synairgen plc (symbole boursier : SNG) a versé un total de 0 dividendes.
Le total des dividendes (ajusté en fonction des divisions d’actions) est de : 0.00
Rendement du dividende (TTM) : 0
Versements de dividendes pour Synairgen plc (SNG) de 2026 à 2026
Versements annuels de dividendes
Année Dividende (ajusté pour divisions d’actions) Changez
Pas assez de données pour les dates fournies.
Liste de tous les paiements de dividendes
Année Dividende Changez
Pas assez de données pour les dates fournies.
Dividendes versés par des entreprises similaires ou concurrentes
Entreprise Nombre de paiements de dividendes Pays
0.00%
US
0.00%
NL
0.00%
CH
0.00%
KR
29.00%
BE